GlassScriptPhysician profile
Perla Zambrano
NPI 1649229980
$6,095.73
in general payments reported to CMS, 2019-2025
46 companies · $1,646 in 2025
The $1,646 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.32 · 2022: $692 · 2023: $1,418 · 2024: $2,295 · 2025: $1,646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,693 · Education: $666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,693.47 |
| Education | $665.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $584.44 | 2021-2025 | Rybrevant, Erleada, Darzalex |
| Pfizer INC. | $391.52 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $360.17 | 2023-2025 | Opdivo, Reblozyl, Krazati |
| Genentech USA, INC. | $348.81 | 2022-2025 | Tecentriq, Itovebi, Phesgo |
| Astrazeneca Pharmaceuticals LP | $336.39 | 2023-2025 | Enhertu, Tagrisso |
| Lilly USA, LLC | $273.77 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $216.66 | 2023-2025 | Enhertu, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $203.64 | 2023-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Novartis Pharmaceuticals Corporation | $193.12 | 2022-2025 | |
| Array Biopharma INC | $187.66 | 2023-2025 | Mektovi, Braftovi, Lorbrena |
| Genzyme Corporation | $179.17 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $172.25 | 2022-2025 | Keytruda, Welireg |
| Mirati Therapeutics, INC. | $169.69 | 2023-2024 | Krazati |
| Beigene USA, INC. | $163.54 | 2022-2024 | Brukinsa |
| Exelixis INC. | $161.73 | 2023-2025 | Cabometyx |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $152.25 | 2023-2024 | Trodelvy |
| Glaxosmithkline, LLC. | $144.15 | 2022-2023 | Jemperli, Zejula |
| Abbvie INC. | $138.37 | 2022-2025 | |
| Incyte Corporation | $131.78 | 2023-2024 | Jakafi, Pemazyre, Monjuvi |
| Pharmacosmos Therapeutics INC. | $120.67 | 2024 | Monoferric |
| Astellas Pharma US INC | $117.82 | 2022 | |
| Puma Biotechnology, INC. | $116.34 | 2024 | |
| Caris Mpi, INC. | $105.98 | 2025 | Mi Cancer Seek |
| Ipsen Biopharmaceuticals, INC | $102.21 | 2023-2025 | Onivyde, Tazverik |
| Aveo Pharmaceuticals, INC. | $90.56 | 2023-2025 | Fotivda |
| Seagen INC. | $84.76 | 2023 | Padcev, Tivdak, Tukysa |
| Emd Serono, INC. | $81.89 | 2023-2025 | Bavencio |
| Bayer Healthcare Pharmaceuticals INC. | $70.99 | 2023-2025 | |
| Amgen INC. | $68.48 | 2022-2025 | Kyprolis |
| Alexion Pharmaceuticals, INC. | $64.79 | 2023-2025 | Ultomiris |
| Tersera Therapeutics LLC | $56.77 | 2024-2025 | Zoladex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.45 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $52.80 | 2025 | Qinlock, Romvimza |
| Sobi, INC | $51.28 | 2023-2024 | |
| Adaptive Biotechnologies Corporation | $46.18 | 2024 | Clonoseq |
| Eisai INC. | $46.08 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $44.99 | 2022-2023 | Givlaari |
| Regeneron Healthcare Solutions, INC. | $40.70 | 2024 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $26.79 | 2023 | Epkinly |
| Immunogen, INC. | $25.71 | 2023 | Elahere |
| Jazz Pharmaceuticals INC. | $23.85 | 2024 | |
| Celgene Corporation | $22.48 | 2022 | |
| Taiho Oncology, INC. | $20.69 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $19.51 | 2023 | Sancuso |
| Beone Medicines USA, INC. | $17.53 | 2025 | Brukinsa |
| Dova Pharmaceuticals | $11.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perla Zambrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.